PFE

Pfizer Inc

Add to Watchlist

Advanced Chart

24.580

+0.35(1.444%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

24.610

Open

24.2899

VWAP

24.50

Vol

36.38M

Mkt Cap

139.75B

Low

24.160

Amount

891.21M

EV/EBITDA(TTM)

7.47

Total Shares

5.67B

186.63B

EV/OCF(TTM)

12.29

P/S(TTM)

2.17

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

13.56B

-1.13%

0.712

-22.61%

17.72B

-0.23%

0.698

+10.87%

17.15B

-3.12%

0.754

-28.82%

Estimates Revision

The market is revising Downward the revenue expectations for Pfizer Inc. (PFE) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by 10.32%.

Revenue Estimates for FY2025

Revise Downward

-0.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.19%

In Past 3 Month

Stock Price

Go Up

+10.32%

In Past 3 Month

18 Analyst Rating

15.46% Upside

Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.38 USD with a low forecast of 24.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

13 Hold

0 Sell

Moderate Buy

15.46% Upside

Current: 24.580

Low

24.00

Averages

28.38

High

33.00

15.46% Upside

Current: 24.580

Low

24.00

Averages

28.38

High

33.00

Citi

Geoff Meacham

Neutral

maintain

$25 -> $26

2025-08-06

New

Reason

Citi

Geoff Meacham

Price Target

$25 -> $26

2025-08-06

New

maintain

Neutral

Reason

Citi analyst Geoff Meacham raised the firm's price target on Pfizer to $26 from $25 and keeps a Neutral rating on the shares. The company reported strong Q2 results but policy headwinds warrant a continued cautious stance, the analyst tells investors in a research note.

BofA

Neutral

maintain

$27 -> $28

2025-08-06

New

Reason

BofA

Price Target

$27 -> $28

2025-08-06

New

maintain

Neutral

Reason

BofA raised the firm's price target on Pfizer to $28 from $27 and keeps a Neutral rating on the shares following Q2 results that were "solid across the board" along with 2025 revenue guidance being maintained and EPS guidance raised "slightly." The firm's new reflects a lower multiple being applied to its underlying 2026 EPS forecast, telling investors that the new multiple reflects Pfizer's below average earnings growth trajectory relative to peers.

BMO Capital

Outperform

NULL

downgrade

$26 -> $15

2025-05-13

Reason

BMO Capital

Price Target

$26 -> $15

2025-05-13

downgrade

Outperform

NULL

Reason

BMO Capital lowered the firm's price target on Terns Pharmaceuticals to $15 from $26 and keeps an Outperform rating on the shares. The company's TERN-701 dose expansion updates are positive with data to come in Q4, and the recent patent correspondences with USPTO indicate reviewers of '601 have removed double patenting rejections in reference to Pfizer's (PFE) danuglipron, the analyst tells investors in a research note. BMO adds however that its price target is reduced as the recent macro headwinds have increased its capital cost assumptions.

Cantor Fitzgerald

Carter Gould

Hold

Initiates

$24

2025-04-22

Reason

Cantor Fitzgerald

Carter Gould

Price Target

$24

2025-04-22

Initiates

Hold

Reason

Cantor Fitzgerald analyst Carter Gould initiated coverage of Pfizer with a Neutral rating and $24 price target. Pfizer made "concrete progress" on its cost-base and margins over 2024, but still underperformed the market for the sixth time in seven years as the upcoming stacking of losses of exclusivity has been an anticipated headwind for "the better part of a decade," the analyst tells investors. The firm still sees consensus that as "overly optimistic" on its views of erosion curves and under-appreciative of competitive pressures on Vyndamax and Prevnar, the analyst added.

UBS

Trung Huynh

Hold

Maintains

$28 → $24

2025-04-08

Reason

UBS

Trung Huynh

Price Target

$28 → $24

2025-04-08

Maintains

Hold

Reason

UBS analyst Trung Huynh lowered the firm's price target on Pfizer to $24 from $28 and keeps a Neutral rating on the shares. The firm says Q1 consensus numbers on Paxlovid and Comirnaty appear too high, but if danuglipron data is disclosed on the day of Q1 results, danu moving into a large Phase 3 obesity program would negate a poor quarter, the analyst tells investors in a research note. UBS says it needs to see a stabilizing tail from the COVID business, continued growth in key assets, and execution on the pipeline to become more constructive on the name.

Goldman Sachs

Asad Haider

Strong Buy

Hold

Downgrades

$32 → $25

2025-04-08

Reason

Goldman Sachs

Asad Haider

Price Target

$32 → $25

2025-04-08

Downgrades

Strong Buy

Hold

Reason

Goldman Sachs downgraded Pfizer to Neutral from Buy with a price target of $25, down from $32, after assuming coverage of the name. The firm says that on the back of a challenging past two years which the company saw downward revisions around COVID related revenue expectations, it expects the shares to remain rangebound. Pfizer faces base business pressure, with greater clarity needed on acquisitions and pipeline levers required to necessitate a sustained stock re-rating, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pfizer Inc (PFE.N) is 8.75, compared to its 5-year average forward P/E of 12.55. For a more detailed relative valuation and DCF analysis to assess Pfizer Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

12.55

Current PE

8.75

Overvalued PE

18.79

Undervalued PE

6.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

9.76

Current EV/EBITDA

7.50

Overvalued EV/EBITDA

13.29

Undervalued EV/EBITDA

6.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

3.00

Current PS

2.24

Overvalued PS

3.60

Undervalued PS

2.41

Financials

Annual

Quarterly

FY2025Q2

YoY :

+10.31%

14.65B

Total Revenue

FY2025Q2

YoY :

+41.21%

4.32B

Operating Profit

FY2025Q2

YoY :

+9264.52%

2.90B

Net Income after Tax

FY2025Q2

YoY :

+5000.00%

0.51

EPS - Diluted

FY2025Q2

YoY :

-50.31%

-1.20B

Free Cash Flow

FY2025Q2

YoY :

-2.14%

67.84

Gross Profit Margin - %

FY2025Q2

YoY :

+127.57%

19.48

FCF Margin - %

FY2025Q2

YoY :

+8513.04%

19.81

Net Margin - %

FY2025Q2

YoY :

+434.94%

8.88

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

64.8K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

499.1K

USD

Months

0-12

28.2K

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 1240.03% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

10.8M

Volume

6-9

Months

806.2K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

78.2K

Volume

Months

6-9

21.8M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

16.0K

USD

3-6

Months

154.0K

USD

6-9

Months

64.0K

USD

0-12

Months

16.0K

USD

Bought

0-3

0.0

USD

Months

3-6

113.0K

USD

Months

6-9

113.5K

USD

Months

0-12

73.0K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

64.8K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

499.1K

USD

Months

0-12

28.2K

USD

Months

PFE News & Events

Events Timeline

2025-08-08 (ET)

2025-08-08

16:11:16

Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA

2025-08-08

09:29:30

Trump, pharma industry discuss increasing medicine spending abroad, Reuters says

2025-08-08

06:37:28

GSK provides update on U.S. settlement CureVac/BioNTech mRNA patent litigation

News

9.5

08-08TipRanks

PinnedPfizer’s (PFE) Turnaround Story Fades as Headwinds Approach

9.0

08-08Globenewswire

PinnedArvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

8.0

01:00 AMWSJ

Exclusive | Trump Weighs Reclassifying Marijuana as Less Dangerous Drug

People Also Watch

Thermo Fisher Scientific Inc

Taiwan Semiconductor Manufacturing Co Ltd

FAQ

What is Pfizer Inc (PFE) stock price today?

The current price of PFE is 24.58 USD — it has increased 1.44 % in the last trading day.

PFE

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

PFE News & Events

Events Timeline

News

People Also Watch

FAQ

What is Pfizer Inc (PFE) stock price today?

What is Pfizer Inc (PFE)'s business?

What is the price predicton of PFE Stock?

What is Pfizer Inc (PFE)'s revenue for the last quarter?

What is Pfizer Inc (PFE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Pfizer Inc (PFE)'s fundamentals?

How many employees does Pfizer Inc (PFE). have?

What is Pfizer Inc (PFE) market cap?